Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis

Pituitary. 2018 Dec;21(6):631-641. doi: 10.1007/s11102-018-0897-z.

Abstract

Purpose: To systematically review the effectiveness of medical treatment for Cushing's syndrome in clinical practice, regarding cortisol secretion, clinical symptom improvement, and quality of life. To assess the occurrence of side effects of these medical therapies.

Methods: Eight electronic databases were searched in March 2017 to identify potentially relevant articles. Randomized controlled trials and cohort studies assessing the effectiveness of medical treatment in patients with Cushing's syndrome, were eligible. Pooled proportions were reported including 95% confidence intervals.

Results: We included 35 articles with in total 1520 patients in this meta-analysis. Most included patients had Cushing's disease. Pooled reported percentage of patients with normalization of cortisol ranged from 35.7% for cabergoline to 81.8% for mitotane in Cushing's disease. Patients using medication monotherapy showed a lower percentage of cortisol normalization compared to use of multiple medical agents (49.4 vs. 65.7%); this was even higher for patients with concurrent or previous radiotherapy (83.6%). Mild side effects were reported in 39.9%, and severe side effects were seen in 15.2% of patients after medical treatment. No meta-analyses were performed for clinical symptom improvement or quality of life due to lack of sufficient data.

Conclusions: This meta-analysis shows that medication induces cortisol normalization effectively in a large percentage of patients. Medical treatment for Cushing's disease patients is thus a reasonable option in case of a contraindication for surgery, a recurrence, or in patients choosing not to have surgery. When experiencing side effects or no treatment effect, an alternate medical therapy or combination therapy can be considered.

Keywords: Cushing’s disease; Cushing’s syndrome; Effectiveness; Medical treatment; Side effects.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Cabergoline / therapeutic use
  • Cushing Syndrome / blood
  • Cushing Syndrome / drug therapy*
  • Cushing Syndrome / radiotherapy*
  • Dopamine Agonists / therapeutic use
  • Humans
  • Hydrocortisone / blood
  • Mitotane / therapeutic use
  • Treatment Outcome

Substances

  • Dopamine Agonists
  • Mitotane
  • Cabergoline
  • Hydrocortisone